| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104; Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322; Program for Biological and Biomedical Science, Harvard Medical School, Boston, MA 02115; National Institute of Advanced Industrial Science and Technology, Sapporo, Japan; ¶ Vaccine Discovery, Wyeth Lederle, Pearl River, NY 10965; || Viral Genomix, Bluebell, PA 19422; and # Basic Research Laboratory and** Metabolism Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
DNA vaccines are a promising technology for the induction of Ag-specific immune responses, and much recent attention has gone into improving their immune potency. In this study we test the feasibility of delivering a plasmid encoding IL-15 as a DNA vaccine adjuvant for the induction of improved Ag-specific CD8+ T cellular immune responses. Because native IL-15 is poorly expressed, we used PCR-based strategies to develop an optimized construct that expresses 80-fold higher than the native IL-15 construct. Using a DNA vaccination model, we determined that immunization with optimized IL-15 in combination with HIV-1gag DNA constructs resulted in a significant enhancement of Ag-specific CD8+ T cell proliferation and IFN-
secretion, and strong induction of long-lived CD8+ T cell responses. In an influenza DNA vaccine model, coimmunization with plasmid expressing influenza A PR8/34 hemagglutinin with the optimized IL-15 plasmid generated improved long term CD8+ T cellular immunity and protected the mice against a lethal mucosal challenge with influenza virus. Because we observed that IL-15 appeared to mostly adjuvant CD8+ T cell function, we show that in the partial, but not total, absence of CD4+ T cell help, plasmid-delivered IL-15 could restore CD8 secondary immune responses to an antigenic DNA plasmid, supporting the idea that the effects of IL-15 on CD8+ T cell expansion require the presence of low levels of CD4 T cells. These data suggest a role for enhanced plasmid IL-15 as a candidate adjuvant for vaccine or immunotherapeutic studies.
This article has been cited by other articles:
|
|
 |
|
  C. Bergamaschi, R. Jalah, V. Kulkarni, M. Rosati, G.-M. Zhang, C. Alicea, A. S. Zolotukhin, B. K. Felber, and G. N. Pavlakis Secretion and Biological Activity of Short Signal Peptide IL-15 Is Chaperoned by IL-15 Receptor Alpha In Vivo J. Immunol., September 1, 2009; 183(5): 3064 - 3072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Laddy, J. Yan, A. S. Khan, H. Andersen, A. Cohn, J. Greenhouse, M. Lewis, J. Manischewitz, L. R. King, H. Golding, et al. Electroporation of Synthetic DNA Antigens Offers Protection in Nonhuman Primates Challenged with Highly Pathogenic Avian Influenza Virus J. Virol., May 1, 2009; 83(9): 4624 - 4630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, R. Kjeken, I. Mathiesen, and D. H. Barouch Recruitment of Antigen-Presenting Cells to the Site of Inoculation and Augmentation of Human Immunodeficiency Virus Type 1 DNA Vaccine Immunogenicity by In Vivo Electroporation J. Virol., June 1, 2008; 82(11): 5643 - 5649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oh, L. P. Perera, M. Terabe, L. Ni, T. A. Waldmann, and J. A. Berzofsky IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis PNAS, April 1, 2008; 105(13): 5201 - 5206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bergamaschi, M. Rosati, R. Jalah, A. Valentin, V. Kulkarni, C. Alicea, G.-M. Zhang, V. Patel, B. K. Felber, and G. N. Pavlakis Intracellular Interaction of Interleukin-15 with Its Receptor {alpha} during Production Leads to Mutual Stabilization and Increased Bioactivity J. Biol. Chem., February 15, 2008; 283(7): 4189 - 4199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ljungberg, A. C. Whitmore, M. E. Fluet, T. P. Moran, R. S. Shabman, M. L. Collier, A. A. Kraus, J. M. Thompson, D. C. Montefiori, C. Beard, et al. Increased Immunogenicity of a DNA-Launched Venezuelan Equine Encephalitis Virus-Based Replicon DNA Vaccine J. Virol., December 15, 2007; 81(24): 13412 - 13423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Boyer, T. M. Robinson, M. A. Kutzler, G. Vansant, D. A. Hokey, S. Kumar, R. Parkinson, L. Wu, M. K. Sidhu, G. N. Pavlakis, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid PNAS, November 20, 2007; 104(47): 18648 - 18653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. P. Perera, T. A. Waldmann, J. D. Mosca, N. Baldwin, J. A. Berzofsky, and S.-K. Oh Development of Smallpox Vaccine Candidates with Integrated Interleukin-15 That Demonstrate Superior Immunogenicity, Efficacy, and Safety in Mice J. Virol., August 15, 2007; 81(16): 8774 - 8783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Arrode, R. Hegde, A. Mani, Y. Jin, Y. Chebloune, and O. Narayan Phenotypic and Functional Analysis of Immune CD8+ T Cell Responses Induced by a Single Injection of a HIV DNA Vaccine in Mice J. Immunol., February 15, 2007; 178(4): 2318 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Kornbluth and G. W. Stone Immunostimulatory combinations: designing the next generation of vaccine adjuvants J. Leukoc. Biol., November 1, 2006; 80(5): 1084 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bolesta, A. Kowalczyk, A. Wierzbicki, C. Eppolito, Y. Kaneko, M. Takiguchi, L. Stamatatos, P. A. Shrikant, and D. Kozbor Increased Level and Longevity of Protective Immune Responses Induced by DNA Vaccine Expressing the HIV-1 Env Glycoprotein when Combined with IL-21 and IL-15 Gene Delivery J. Immunol., July 1, 2006; 177(1): 177 - 191. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
